A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-01 and is reviewed periodically as new material appears.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
==== Differential ==== A differential backup saves only the data that has changed since the last full backup. This means a maximum of two backups from the repository are used to restore the data. However, as time from the last full backup (and thus the accumulated changes in data) increases, so does the time to perform the differential backup. Restoring an entire system requires starting from the most recent full backup and then applying just the last differential backup. A differential backup copies files that have been created or changed since the last full backup, regardless of whether any other differential backups have been made since, whereas an incremental backup copies files that have been created or changed since the most recent backup of any type (full or incremental). Changes in files may be detected through a more recent date/time of last modification file attribute, and/or changes in file size. Other variations of incremental backup include multi-level incrementals and block-level incrementals that compare parts of files instead of just entire files.
=== Spintronics === Large-area graphene created by chemical vapor deposition (CVD) and layered on a SiO2 substrate, can preserve electron spin over an extended period and communicate it. Spintronics varies electron spin rather than current flow. The spin signal is preserved in graphene channels that are up to 16 micrometers long over a nanosecond. Pure spin transport and precession extended over 16 μm channel lengths with a spin lifetime of 1.2 ns and a spin diffusion length of ≈6 μm at room temperature. Spintronics is used in disk drives for data storage and in magnetic random-access memory. Electronic spin is generally short-lived and fragile, but the spin-based information in current devices needs to travel only a few nanometers. However, in processors, the information must cross several tens of micrometers with aligned spins. Graphene is the only known candidate for such behavior.
== Mode of action == The molecular mechanism of inhibiting mechanosensitive channels by GsMTx-4 is bilayer-dependent. Rather than directly binding to the gating structures like other ICK peptides do, GsMTx4 makes the mechanosensitive channels less sensitive to mechanical tension of the bilayer membrane. By its tension-dependent insertion into the membrane, GsMTx4 is thought to distort the distribution of tension near mechanosensitive channels, which will make the transfer of force from the bilayer to the channel less efficient. Unlike other ICK peptides, the action of GsMTx-4 is not stereospecific, as both L- and D-GsMTx-4 can block MSCs.
Sources: en.wikipedia.org
Everyone, Wherever You Are, Come One Step Closer: Questions about God. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-5628-1. OCLC 1389811523. Kermani, Navid (2023). What Is Possible Now: 33 Political Situations. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-5764-6. OCLC 1378713376. Kermani, Navid (2026): In the Other Direction Now. Dispatches from East Africa. Haus Publishing, London 2026, ISBN 978-1-914982-22-4. Translated by Tony Crawford; In die andere Richtung jetzt. Eine Reise durch Ostafrika. C.H. Beck, München 2024, ISBN 978-3-406-81969-8; Rezension von Wolfram Schütte.
== History == The historical events leading to the proposal of the Good Laboratory Practice (GLP) regulations are crucial for understanding why these regulations are important to improve the quality and integrity of chemical safety data. They were developed in response to concerns about the reliability of toxicity data from industry. The GLP regulations aim to standardize procedures and practices to ensure accurate, reliable, and traceable safety data. GLP was first introduced in New Zealand and Denmark in 1972, but only as quality standards for re-agents and lab materials (first created in Australia due to being isolated from western labs by the Japanese blockade of WW2); the US FDA heard about them from NZ at an international conference just as the below IBT scandal broke). During the 1960s and 1970s, a growing concern for environmental issues and health impacts of chemicals was one factor in increased federal regulation, particularly in the chemical and pharmaceutical sectors, leading to more stringent product testing requirements and the development of inspection programs targeting laboratories conducting animal research in developed countries. These initiatives, initiated in the US by the Office of New Drugs and the Office of Marketed Drugs in 1969 and later expanded with the Office of Compliance, included inspections of facilities with questionable study validity or misconduct tips, revealing significant quality control issues and deficiencies in animal toxicological testing standards and data reporting.
Glycopeptides are peptides that contain carbohydrate moieties (glycans) covalently attached to the side chains of the amino acid residues that constitute the peptide. Over the past few decades it has been recognised that glycans on cell surface (attached to membrane proteins or lipids) and those bound to proteins (glycoproteins) play a critical role in biology. For example, these constructs have been shown to play important roles in fertilization, the immune system, brain development, the endocrine system, and inflammation. The synthesis of glycopeptides provides biological probes for researchers to elucidate glycan function in nature and products that have useful therapeutic and biotechnological applications.
Sources: en.wikipedia.org
As a consequence of the initial competing claims of discovery, an element naming controversy arose. Since the Soviets claimed to have first detected the new element they suggested the name kurchatovium (Ku) in honor of Igor Kurchatov (1903–1960), former head of Soviet nuclear research. This name had been used in books of the Soviet Bloc as the official name of the element. The Americans, however, proposed rutherfordium (Rf) for the new element to honor New Zealand physicist Ernest Rutherford, who is known as the "father" of nuclear physics. In 1992, the IUPAC/IUPAP Transfermium Working Group (TWG) assessed the claims of discovery and concluded that both teams provided contemporaneous evidence to the synthesis of element 104 in 1969, and that credit should be shared between the two groups. In particular, this involved the TWG performing a new retrospective reanalysis of the Russian work in the face of the later-discovered fact that there is no 0.3-second isotope of element 104: they reinterpreted the Dubna results as having been caused by a spontaneous fission branch of 259Rf. The American group wrote a scathing response to the findings of the TWG, stating that they had given too much emphasis on the results from the Dubna group. In particular they pointed out that the Russian group had altered the details of their claims several times over a period of 20 years, a fact that the Russian team does not deny.
The death of Ali Khamenei triggered an election for a new supreme leader. Under the terms of Iran's constitution, the Interim Leadership Council was established on 1 March to exercise the functions of Iran's head of state until a new supreme leader is elected. Mojtaba Khamenei was elected on 8 March 2026 to replace his father as supreme leader, and the IRGC, as well as Iran's top leaders, including Mohammad Bagher Ghalibaf, Ali Larijani, and Masoud Pezeshkian, pledged their allegiance to him. In late March, the NYT described Iran's leadership as paralyzed with severely disrupted decision-making process. It also reported that the damage to communications infrastructure caused paranoia and internal power struggles. As of 21 May, Khamenei remains in hiding and the de facto ruler is uncertain. The IRGC is currently under command of the hardliner general Ahmad Vahidi, who is cited as the formulator of Iran's military and negotiation stance. The Telegraph has revealed a shadowy partnership with the retired IRGC commander-in-chief Mohammad Ali Jafari.
(2026) report new mitogenomes of at least 7 Neanderthal individuals from the Stajnia Cave (Poland), interpreted as likely dating to Marine Isotope Stage 5, find that the studied individual carried mitochondrial DNA lineages related to those Western Europe and the northern Caucasus, and interpret their findings as possible evidence of a widespread mitochondrial DNA lineage that was subsequently replaced by the mtDNA found in late Neanderthals. Evidence of exploitation of European pond turtles by Neanderthals occupying the Neumark-Nord site (Germany) during the Last Interglacial is presented by Gaudzinski-Windheuser et al. (2026). Palancar et al. (2026) provide evidence of a clear morphological distinction between axes of Neanderthals and modern humans on the basis of the study of a Neanderthal axis from the Sidrón Cave (Spain). Evidence from the study of metacarpal remains from the Sidrón Cave indicative of differences of metacarpal morphology of Neanderthals and modern humans is presented by Rosas et al. (2026). Rodrigo et al. (2026) provide evidence from the study of animal remains from the Fumane Cave (Italy) indicative of a structured subsistence strategy of Neanderthals occupying the site, including processing of carcasses at kill locations and selective transport of high-yield portions of the carcasses into the cave for secondary processing. Burke et al.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.